1. 1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists
2. aArista, L.; Bonanomi, G.; Capelli, A. M.; Damiani, F.; Di-Fabio, R.; Gentile, G.; Hamprecht, D.; Micheli, F.; Tarsi, L.; Tedesco, G.; Terreni, S.PCT Int. Appl. WO/2005/080382, 2005.
3. bBonanomi, G.; Checchia, A.; Fazzolari, E.; Hamprecht, D.; Micheli, F.; Tarsi, L.; Terreni, S.PCT Int. Appl. WO/2006/108701, 2006.
4. cArista, L.; Cardullo, F.; Cecchia, A.; Hamprecht, D.; Micheli, F.; Tedesco, G.; Terreni, S.PCT Int. Appl. WO/2006/133946, 2006.
5. The ICH Guidance Q8 represents the U.S. Food and Drug Administration (FDA) current thinking on Pharmaceutical Development manufacturing process. This guidance describes the suggested contents to input in a regulatory submission providing an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process. This guidance is part of a set of Guidance for Industry developed within the Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).